NCT03495297

Brief Summary

This study will test the hypothesis that implantation of a subcutaneous implantable cardioverter defibrillator (S-ICD) without performing a defibrillation test is non-inferior to S-ICD implant with a defibrillation test with regards to the primary endpoint failed first shock in a spontaneous arrhythmia episode when implant position is confirmed with PRAETORIAN score.

Trial Health

58
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
965

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2018

Longer than P75 for not_applicable

Geographic Reach
4 countries

32 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 23, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

April 12, 2018

Completed
25 days until next milestone

Study Start

First participant enrolled

May 7, 2018

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

February 3, 2025

Status Verified

January 1, 2025

Enrollment Period

6.9 years

First QC Date

March 23, 2018

Last Update Submit

January 30, 2025

Conditions

Keywords

subcutaneous implantable cardioverter defibrillatorDefibrillation testing

Outcome Measures

Primary Outcomes (1)

  • Failed first appropriate shock in a spontaneous episode

    Number of patients having experiences a failed first appropriate shock in a spontaneous arrhythmia episode

    40 months

Secondary Outcomes (20)

  • DFT related complications

    24 hours or 30 days

  • PRAETORIAN Score

    up to 24 hours

  • Pain post implant

    1-4 hours post implant

  • Appropriate ICD therapy

    40 months

  • Inappropriate ICD therapy

    40 months

  • +15 more secondary outcomes

Study Arms (2)

S-ICD Implant with defibrillation test

NO INTERVENTION

Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant

S-ICD Implant without defibrillation test

EXPERIMENTAL

Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant

Procedure: ommitence of defibrillation testing

Interventions

Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted

S-ICD Implant without defibrillation test

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who meet current guidelines for ICD therapy and intent to undergo a de novo implant procedure for an S-ICD
  • Patients must pass S-ICD screening per local routine
  • Patients over 18 years of age, willing and capable to give informed consent
  • Patients must be willing and capable of complying to follow up visits
  • Patient must be eligible for either DFT strategy per physician discretion

You may not qualify if:

  • Patient with a life expectancy shorter than 12 months due to any medical condition
  • Patients known to be pregnant
  • Patients with intracardiac thrombus
  • Patients with atrial fibrillation without appropriate anticoagulation
  • Patients likely to undergo heart transplant within 12 months
  • Patients with LVAD
  • Patients with other contra-indications for DFT per physician's discretion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (32)

Adventh Health System

Orlando, Florida, 32803, United States

Location

Emory University Hospital

Atlanta, Georgia, 30322, United States

Location

CorVita Science Foundation

Chicago, Illinois, 60605, United States

Location

Englewood Hospital and Medical Center

Englewood, New Jersey, 07631, United States

Location

Mount Sinai Beth Israel

New York, New York, 10003, United States

Location

Icahn School of Medicine at Mount Sinaï

New York, New York, 10029, United States

Location

Erlanger Health System

Chattanooga, Tennessee, 37403, United States

Location

Asklepios Kliniken

Hamburg, Germany

Location

Universitätsklinikum Schleswig-Holstein

Kiel, Germany

Location

Universitätsklinikum Schleswig-Holstein, Campus Lübeck

Lübeck, Germany

Location

Universitätsklinikum Mannheim

Mannheim, Germany

Location

Universitätsklinikum Würzburg

Würzburg, Germany

Location

Flevoziekenhuis

Almere Stad, Netherlands

Location

Academic Medical Center Amsterdam

Amsterdam, Netherlands

Location

OLVG

Amsterdam, Netherlands

Location

Albert Schweitzer Ziekenhuis

Dordrecht, Netherlands

Location

Catharina Ziekenhuis

Eindhoven, Netherlands

Location

UMCG

Groningen, Netherlands

Location

Spaarne Gasthuis

Haarlem, Netherlands

Location

Medisch Centrum Leeuwarden

Leeuwarden, Netherlands

Location

St Antonius Ziekenhuis

Nieuwegein, Netherlands

Location

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands

Location

Isala Klinieken

Zwolle, Netherlands

Location

Basildon and Thurrock Univerity Hospital NHS Foundation Trust

Basildon, United Kingdom

Location

Blackpool Victoria Hospital NHS Foundation Trust

Blackpool, United Kingdom

Location

Royal Papworth Hospital NHS Foundation Trust

Cambridge, United Kingdom

Location

Heart and Chest Hospital NHS Foundation Trust

Liverpool, United Kingdom

Location

Barts Health NHS Trust of the Royal London Hospital

London, ÉC1A 7BE, United Kingdom

Location

Manchester Heart Center, Manchester Royal Infirmary

Manchester, M13 9WL, United Kingdom

Location

Oxford University Hospitals NHS Foundation Trust

Oxford, OX3 7LE, United Kingdom

Location

Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital

Sheffield, United Kingdom

Location

The Royal Wolverhampton NHS Trust, the New Cross Hospital

Wolverhampton, United Kingdom

Location

Related Publications (1)

  • Quast ABE, Baalman SWE, Betts TR, Boersma LVA, Bonnemeier H, Boveda S, Brouwer TF, Burke MC, Delnoy PPHM, El-Chami M, Kuschyk J, Lambiase P, Marquie C, Miller MA, Smeding L, Wilde AAM, Knops RE. Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. Am Heart J. 2019 Aug;214:167-174. doi: 10.1016/j.ahj.2019.05.002. Epub 2019 May 16.

    PMID: 31220775BACKGROUND

Study Officials

  • Reinoud E Knops, MD, PhD

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 23, 2018

First Posted

April 12, 2018

Study Start

May 7, 2018

Primary Completion

April 1, 2025

Study Completion

July 1, 2025

Last Updated

February 3, 2025

Record last verified: 2025-01

Locations